AIM IMMUNOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4282 USD | +5.34% |
|
-7.91% | -2.66% |
Presenter SpeechJenene Thomas (Attendees)Okay. We are ready to get started. Good afternoon, an...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Calendar
2024-05-15
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.4282
USD
Average target price
2.75
USD
Spread / Average Target
+542.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.66% | 21.37M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- Transcript : AIM ImmunoTech Inc. - Special Call
